ALNY - candlestick chart analysis of Alnylam Pharmaceuticals Inc.

Popular stocks today

AAPL ALB AMZN BIIB BLNK CAT GOOG MSFT MUFG NVDA PEP PFE PLTR QQQ SMCI SMH SPY TSLA VRTX VTI

Membership
- Log In
- Log Out
- Sign Up
- About HotCandlestick
- Benefits
- Help
Candlestick Charts
Chart Education
Trading Tools
Opportunities
External Links

Official PayPal Seal

As Seen In...

The Complete Guide to Using Candlestick Charting: How to Earn High Rates of Return safely

End of day quotes updated Wed Oct 9 15:53 CST
🏠

⎙

🔍

◄ Daily Pattern ► ◄ Weekly Pattern ► ◄ Monthly Pattern ► ◄ Quarterly Pattern ►
Bullish Ladder Bottom Bearish Harami Bearish Engulfing Bullish Engulfing
25-Sep-2024 01-Mar-2024 29-Sep-2023 30-Jun-2020
-23.2 strength -86.8 strength -61 strength 23.4 strength

ALNY	SPY
-0.1 1.1 -1.5 -1.5 41.5	0.7 0.7 0.6 0.6 22.2
% Price Gain WTD Performance (%) MTD Performance (%) QTD Performance (%) YTD Performance (%)
SPY tracks the S&P 500 index w/dividends.

ALNY News
9-Oct-2024 6:00 AM CST - Business Wire Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of its supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran is the generic name for AMVUTTRA, which is currently approved by the U.S. FDA for the treatment of the po
29-Sep-2024 8:00 AM CST - Business Wire Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that two new data sets from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), were presented in the Late Breaking Clinical Research Session 1 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024, which was held virtually. An o
26-Sep-2024 7:00 AM CST - Business Wire Alnylam to Webcast TTR Investor Day Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Day event on the Investors section of the Companys website, www.alnylam.com, on Wednesday, October 9, 2024 at 8:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event. The TTR Investor Day will feature presentations from Alnylams management team, including senior leaders from

Disclaimer Privacy Contact

Copyright © 2001-2024, All rights reserved.
HotCandlestick.com, LLC

ALNY News
9-Oct-2024 6:00 AM CST - Business Wire Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of its supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran is the generic name for AMVUTTRA, which is currently approved by the U.S. FDA for the treatment of the po
29-Sep-2024 8:00 AM CST - Business Wire Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that two new data sets from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), were presented in the Late Breaking Clinical Research Session 1 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024, which was held virtually. An o
26-Sep-2024 7:00 AM CST - Business Wire Alnylam to Webcast TTR Investor Day Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Day event on the Investors section of the Companys website, www.alnylam.com, on Wednesday, October 9, 2024 at 8:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event. The TTR Investor Day will feature presentations from Alnylams management team, including senior leaders from